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Abstract: The most active metabolite of vitamin D is 1α,25-dihydroxyvitamin D3, which is a central
regulator of mineral homeostasis: excessive administration leads to hypercalcemia. Additionally,
1α,25-dihydroxyvitamin D3 is important to decision-making by cells, driving many cell types to
growth arrest, differentiate and undergo apoptosis. 1α,25-Dihydroxyvitamin D3 regulates gene
transcription by binding to a single known receptor, the vitamin D receptor. Rapid intracellular
signals are also elicited in vitro by 1α,25-dihydroxyvitamin D3 that are independent of transcription.
There are many aspects of the multiple actions of 1α,25-dihydroxyvitamin D3 that we do not fully
understand. These include how a single receptor and provoked rapid events relate to the different
actions of 1α,25-dihydroxyvitamin D3, its calcemic action per se, and whether a large number of genes
are activated directly, via the vitamin D receptor, or indirectly. A strategy to resolving these issues
has been to generate synthetic analogues of 1α,25-dihydroxyvitamin D3: Some of these separate
the anti-proliferative and calcemic actions of the parent hormone. Crystallography is important
to understanding how differences between 1α,25-dihydroxyvitamin D3- and analogue-provoked
structural changes to the vitamin D receptor may underlie their different activity profiles. Current
crystallographic resolution has not revealed such information. Studies of our new analogues have
revealed the importance of the A-ring adopting the chair β-conformation upon interaction with the
vitamin D receptor to receptor-affinity and biological activity. Vitamin D analogues are useful probes
to providing a better understanding of the physiology of vitamin D.
Keywords: cell differentiation; vitamin D; vitamin D receptor; vitamin D analogues; crystallography
1. Introduction
1α,25-Dihydroxyvitamin D3 (1,25D3, calcitriol, Figure 1) is the most active metabolite of vitamin D
(vitD, cholecalciferol). This seco-steroid hormone has many biological roles [1]. A key physiological role
of 1,25D3 is to regulate the absorption and transportation of essential minerals, particularly calcium,
phosphorus, and magnesium, which are important to the maintenance of bone [2,3]. 1,25D3 also plays
a key role in decision-making by cells because it can elicit events that result in many types of cells
arresting their growth, differentiating, and undergoing apoptosis. The anti-proliferative action of
1,25D3 extends to malignant cells, leading to interest in its use for differentiation therapy of leukemia
and other cancers. However, a substantial limitation to this use of 1,25D3 is that its calcemic action
restricts achieving an effective therapeutic dose [4]. Many of the immune cell types express the receptor
for vitamin D (VDR): 1,25D3 has an important role in their function and is, therefore, important to
good health [5,6]. A related interest is the therapeutic use of 1,25D3 as an anti-inflammatory agent.
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biotransformation of sterols into 9,10-seco-steroids (vitD), and it was not specifically biosynthesized 
for vitD. Additionally, the CD-ring is the only part of the vitD molecule that does not participate in 
the metabolic transformations of vitD. Moreover, molecular modeling revealed that des-C,D 
analogues relate structurally to the biotransformation product [29] of all-trans-retinoic acid (ATRA), 
a potent differentiating agent. Des-C,D analogues combine aspects of both the vitD and retinoid 
structures, and we call them retiferols. Our original concept of retiferols led to the synthesis of a 
substantial variety of CD-ring modified analogues, including other des-C,D analogues [30], des-D,C-
ring analogues [31], and des-C,D-ring homo analogues [32], and their biological activity was 
evaluated [30–32]. Our first retiferol (Figure 2) RAD2 became a synthetic target [33]. Roche researchers 
[30] obtained 19-nor RAD2 and reported that this analogue was useful in the treatment of hyper-
proliferative skin diseases in vivo. Here, we discuss how CD-ring modifications affect activity. 
 
Figure 2. The structure of RAD2, the first des-C,D analogue of 1α,25-dihydroxyvitamin D3 and of (20S)-
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Figure 1. The structures of 1α,25-dihydroxyvitamin D3 (1,25D3) and 1α,25-dihydroxyvitamin
D2 (1,25D2).
2. The Mod of Action of Vitamin D
Some of the biological effects of 1,25D3 result from the direct activation of target genes [7,8]. In this
case, 1,25D3 binds to its single known receptor VDR. The VDR forms a heterodimer with the retinoid X
receptor to regulate gene transcription. 1,25D3 regulates a large number of genes, including ones that
link to the growth and differentiation of cells and diseases that include cancer, diabetes, and arthritis.
At least 229 genes are subject to regulation by 1,25D3, as revealed by ChiP-seq analysis [9,10]. We do
not understand whether the VDR activates all of the envisaged number of genes directly or indirectly.
For some cells, 1,25D3 treatment leads to the activation of non-genomic signaling pathways.
The delineation of these events is from in vitro studies, and they occur within seconds or minutes after
treating cells with 1,25D3 [11,12]. In this scenario, 1,25D3 initiates signals at the plasma membrane
or in the cytosol. The mitogen-activated protein kinases and phosphatidylinositol 3-kinase signaling
cascades mediate this rapid response to some extent [13–15]. There are putative receptors for 1,25D3
at the cell membrane that include the membrane-associated rapid response steroid-binding protein
(MARRS, ERp57, or PDIA3), megalin, and cubilin, and the latter two transport vitamin D, complexed
to its serum binding protein [16]. Additionally, 1,25D3 binds to the VDR in an alternative VDR-binding
pocket through a 6-cis-1,25D conformation as proposed by Mizwicki and Norman [17]. Endocytosis
of this and other putative membrane receptors can generate immediate intracellular signals via the
Rab5/PI3-kinase pathway. A shift in the balance between VDR-provoked gene transcription and rapid
signaling events might underlie the anti-proliferative versus calcemic actions of 1,25D3. However,
the structure-calcemic activity relationship for most of the known vitamin D analogues is not clear
to date.
3. Vitamin D Analogues
Over recent years, investigators have generated and studied hundreds of vitD analogues and
several metabolites. Their structures are important to biological activity. A total of 17 crystal structures
of 1α-hydroxylated vitDs are at the Cambridge Structural Database, and there are structures of 63 vitD
analogues bound to the engineered VDR. Despite all of this, we still do not understand the molecular
events that force an analogue to adopt the A-ring slightly distorted chair β-conformation per se and
when bound to the VDR. It remains a mystery as to why the three hydroxyls (1, 3, and 25) that mediate
analogue binding to the VDR are almost overlapping and why analogues have very different structures
and activities.
The most important parts of vitD and analogues regarding the affinity for the VDR,
and consequently activity profile, are the A-ring, the side-chain, and the CD-ring system.
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Recently, we divided double point modified (DPM) analogues of vitDs [18] into structural
groups. We introduced the new classification system for semi-quantifying the biological activities of
DPM analogues and outlined new directions for structural modifications. Based on this overview,
we designed new analogues of 1α,25-dihydroxyvitamin D2 (Figure 1, 1,25D2) to study the active
conformation of the A-ring. We used a panel of closely related analogues of 1,25D2, [19] with solved
crystal structures [20], rather than just a single analogue. For reference, we used a new compound (not
shown) with all the functional groups (C-25 carboxy and 1- and 3-hydroxyl) protected and, therefore,
deprived of electrostatic interactions [20]. The correlation of the structures of the new analogues with
their biological activities [21,22] allowed us to solve a long-lasting enigma [23,24] surrounding the
1α-hydroxylated analogues of vitD. We have proposed a new general rule (see below), confirmed by
theoretical calculations, which applies to all of our crystallographic data and which has been obtained
for 1α -hydroxylated analogues of vitD over the last 25 years.
We investigated the side-chain structure by generating (24Z) geometric isomers [25] of our
hypocalcemic analogues of 1,25D2. We examined their binding affinities for the VDR, the potency
regarding inhibition of cell growth, and the regulation of stem cell-related gene expression in colon
cancer cells [26]. Resistance to hCYP24A1-metabolism, which deactivates 1,25D3 by enzymatic
hydroxylation [25], relates to a preferred side-chain geometry. An extended and rigidified side-chain
of 1,25D2 is responsible for the longer-term biological effects of vitD (see below). We used human
AML cell lines to examine the correlation between the side-chain geometry of 1,25D2 and potency in
arresting cell growth and inducing cell differentiation [27].
The original principle of CD-ring modified analogues [28] was that the entire CD-ring system of
an analogue was not required for activity [29]. The hydrindane CD-ring moiety originates from the
biotransformation of sterols into 9,10-seco-steroids (vitD), and it was not specifically biosynthesized for
vitD. Additionally, the CD-ring is the only part of the vitD molecule that does not participate in the
metabolic transformations of vitD. Moreover, molecular modeling revealed that des-C,D analogues
relate structurally to the biotransformation product [29] of all-trans-retinoic acid (ATRA), a potent
differentiating agent. Des-C,D analogues combine aspects of both the vitD and retinoid structures,
and we call them retiferols. Our original concept of retiferols led to the synthesis of a substantial variety
of CD-ring modified analogues, including other des-C,D analogues [30], des-D,C-ring analogues [31],
and des-C,D-ring homo analogues [32], and their biological activity was evaluated [30–32]. Our first
retiferol (Figure 2) RAD2 became a synthetic target [33]. Roche researchers [30] obtained 19-nor RAD2
and reported that this analogue was useful in the treatment of hyper-proliferative skin diseases in vivo.
Here, we discuss how CD-ring modifications affect activity.
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Figure 2. The structure of RAD2, the first des-C,D analogue of 1α,25-dihydroxyvitamin D3 and of
(20S)-13,13-dimethyl-des-C,D-1,25-dihydroxy-2-methylene-19-nor-vitamin D3.
Below, we examine the use of various classes of new analogues of vitD to unravel some of the
issues relating to structure and biological activity. Of particular importance is that new analogues
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separate the anti-proliferative and calcemic actions of the parent hormone more effectively than
previous analogues (see below), and how might this be the case?
4. The Vitamin D A-Ring Conformation
To investigate the correlation between the A-ring conformation and activity, we conceived and
synthesized, by a novel convergent strategy, a panel of DPM analogues of 1,25D2 coded PRI-1730,
PRI-1731, PRI-1732, PRI-1733, and PRI-1734 (Figure 3) [19]. Our modifications included new 5,6-trans
(5E,7E) geometry of the A-ring per se or combined with the further modifications in the side chain.
These included an additional (22S)-hydroxyl, 22,23-single bond, and a reversed absolute configuration
(24-epi) at C-24. All our analogues induced differentiation of the VDR positive A375 and VDR negative
SK-MEL 188b human malignant melanoma cell lines [22]. As expected, 5,6-trans modification of the
A-ring was advantageous to enhancing the anti-proliferative activity of the analogues but not as a
single point modification. Very unexpectedly, the additional 22-hydroxyl in the side-chain, conceived
to enhance VDR binding, reduced significantly the anti-proliferative activity of both the natural and
5,6-trans series of analogues [21].
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PRI-1731 and PRI-1733 increased translocation of the VDR to the nucleus of HL60 cells but to a
lesser exte t t a r e 1,25 2 and 1,25D3. 5,6-Trans modification contributed substantially to
the increased stability of the PRI-1731 and PRI-1733 against enzymatic hydroxylation by hCYP24A1,
produced by expressing recombinant protein in Escherichia coli. Unexpectedly, reversing the chirality at
C-24 from the natural (24S) in PRI-1731 to the (24R) in PRI-1733 did not affect metabolic resistance.
The conversion remained at the high level of only 12% for both analogues, compared with 44% and 35%
for 1,25D3 and 1,25D2, respectively. The addition of 22-hy roxyl and the saturatio of the 22,23-double
bond resulted in a dramatic loss of metabolic stability from 12% for PRI-1731 to a 52% conversion for
PRI-1732. We used fluorescence polarization-based competition assay to measure the binding affinity of
our a alogues for the VDR. Only the 5,6-trans analogue of 1,25D2 (PRI-1731) showed a binding affinity
comparable to that of both 1,25D2 and 1,25D3. Very intriguingly, a combination of all four structural
modifications resulted in a complete loss of activity in the case of PRI-1734. This analogue showed
weak binding to the VDR [21] and failed to agonize the VDR. However, its structure might be a good
starting point for the design of a vitD antagonist, once the binding is improved [21]. The modifications
introduced have not led to an increase in differentiation-inducing potency for the above new panel of
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analogues. However, they have resulted in a very divergent group of analogues that have provided
very important data regarding structure versus activity relationships.
VitD analogues are resistant to crystallization due to a high flexibility over the number of rotated
single bonds in the side-chain and in the triene system. Therefore, we were very fortunate to obtain
single crystals of as many as three analogues (PRI-1730, PRI-1731, and PRI-1732), out of a panel of
our five analogues [19], suitable for X-ray diffraction. For our structure–activity relationship, it was
also of key importance to obtain a single crystal of the synthetic intermediate with all the functional
groups (1,3, and 25-hydroxyl and 25-carboxyl) protected and, therefore, deprived of electrostatic
interactions [25]. Very interestingly, we observed that the A-ring of PRI-1730 and PRI-1731 exists in
a crystal state in a chair β-conformation, and that of PRI-1732 and of the totally protected synthetic
intermediate in a chair α-conformation [20]. Using this unusually large collection of solid-state
structures, our crystallography study revealed the new general rule regarding the solid-state A-ring
conformation. We concluded that the direct hydrogen bond between 1-hydroxyl and 3-hydroxyl of the
neighboring molecule forces the A-ring of 1α-hydroxylated analogues of vitamin D to adopt the chair
β-conformation. According to our rule, the analogues adopting an A-ring chair β-conformation exhibit
higher biological activity than the structurally related analogues existing in the chair α-conformation.
This is due to the possibility of stronger electrostatic interactions of the chair β-conformation with the
VDR. This explains why PRI-1730, which adopts the chair β-conformation, shows much higher activity
(e.g., in nuclear translocation of the VDR) than PRI-1732, which has the chair α-conformation, and why
PRI-1730 shows a much higher metabolic stability (31% conversion) than PRI-1732 (52% conversion).
Contrary to the common understanding, our crystallographic studies demonstrated that the structure
of an analogue in a solid state very much relates to its structure in a solution and when interacting with
the VDR, predicts its biological activity as high or low. We should consider testing only the analogues
existing in a solid state in A-ring chair β-conformation for biological activity.
5. Modifications to the Vitamin D Side-Chain
In our studies of the relationship between the side-chain structure and activity, we developed
another new convergent strategy to modify our leading 1,25D2 analogues, PRI-1906 and PRI-1907
(Figure 4). We extended and rigidified the side-chain and obtained new analogues, PRI-1916 and
PRI-1917, with the previously unknown geometry at C-24 [(24Z), instead of (24E)]. The binding affinity
of PRI-1916, with two methyl at the terminus of the side-chain at C-25, for the full-length human VDR
in a fluorescence polarization assay was substantially higher than that of the previously obtained
PRI-1906. However, the affinity of PRI-1917, with two ethyl at C-25, was much lower than that of the
parent PRI-1907. This finding indicated that terminal alkyls at C-25 strongly influence the binding
affinity of analogues for the VDR. Our PRI-1906 and PRI-1907 have a very high resistance to metabolic
conversion (2.3% and 0.8% for PRI-1906 and PRI-1907, respectively, compared with 44% and 35%
for 1,25D3 and 1,25D2, respectively). Our new PRI-1916 and PRI-1917 showed a somewhat lower
resistance to conversion, although still higher than that of 1,25D3 and 1,25D2. From these findings we
proved that a rigid and straight (24E) geometry of the side-chain is preferred for metabolic resistance,
and in keeping (24E), (24-trans) analogues elicit long-term biological effects against cancer cells [25].
(24Z) Modification of the side-chain of 1,25D2 analogues has a contrasting effect on the differentiating
activity of PRI-1906 and PRI-1907. Although the VDR affinity of the (24Z) analogue PRI-1916 was
lower than that of (24E) analogue PRI-1906, the potency of PRI-1916 was slightly higher than that of
PRI-1906 when tested against the human AML cell lines KG-1a, HL60, U937, and MOLM-13, which
typify different stages of myeloid maturation [27] However, PRI-1917 was significantly less potent
than PRI-1907. We, therefore, finally concluded that the (24E) side-chain geometry combined with
selected modifications of the A-ring is preferable in terms of generating potent anti-proliferative and
differentiating vitDs. Evaluation of the differentiating activity and calcemic action of newer analogues
of 1,25D2 has shown they are more potent differentiating agents than 1,25D3 and have a reduced
calcemic action (see Table 1).
Int. J. Mol. Sci. 2018, 19, 2119 6 of 11
Int. J. Mol. Sci. 2018, 19,  6 of 11 
 
analogues of 1,25D2 has shown they are more potent differentiating agents than 1,25D3 and have a 
reduced calcemic action (see Table 1). 
Table 1. Differentiating potency, calcemic action, and binding to the receptor for vitamin D (VDR) of 
PRI analogues of 1α,25-dihydroxyvitamin D2. 
Analogue 
Differentiation  
EC50 m × 10−11 
Calcaemic Action  
Ca2+ (Serum) m × 10−6 
VDR Binding  
IC50 m × 10−10 
1,25D3 53 107 23 
PRI-1907 6 75 62 
PRI-5100 113 86 6 
PRI-5101 118 90 5 
PRI-5201 3 93 11 
PRI-5202 2 81 36 
The values obtained for 1α,25-dihydroxyvitamin D3 (1,24D3) are shown for comparison. The 
EC50 for differentiating potency is the value that drives half-maximal differentiation of the 
promyeloid cell line HL60 towards neutrophils. Calcium levels are the mean of the values obtained 
for five mice treated with 0.3 µg/kg of 1,25D3 or an analogue every other day for 3 weeks and 
measured on day 21. The serum calcium level in ethanol-treated mice was 62 µM. The analogues PRI-
1907, PRI-5201, and PRI-5202 are more potent differentiating agents than 1,25D3 and have a lower 
calcemic action. 
 
Figure 4. The side-chain extended and rigidified analogues of 1α,25-dihydroxyvitamin D2 (PRI-1906 
and PRI-1907) and their (24Z) geometric isomers (PRI-1916 and PRI-1917). 
Quite unexpectedly, both (24E) and the new (24Z) analogues are equipotent in decreasing the 
cloning capacity and the proliferative activity of the human colon cancer cells HT-29 [26]. These cells 
are refractory to the anti-proliferative action of the chemotherapeutic agent 5-flurouracil. Both of the 
C-25 diethyl analogues, PRI-1907 and PRI-1917, decreased the level of expression of stemness-related 
genes, while both dimethyl analogues, PRI-1906 and PRI-1916, were not able to downregulate these 
genes. Therefore, the new geometric analogues, PRI-1907 and PRI-1917, are good candidates for 
further studies to examine the benefit to preventing cancer relapse. In this regard, they act to decrease 
the proliferative capacity of cells that initiate tumor regrowth, by virtue of downregulating stemness-
Figure 4. The side-chain extended and rigidified analogues of 1α,25-dihydroxyvitamin D2 (PRI-1906
and PRI-1907) and their (24Z) geometric isomers (PRI-1916 and PRI-1917).
Table 1. Differentiating potency, calcemic action, and binding to the receptor for vitamin D (VDR) of
PRI analogues of 1α,25-dihydroxyvitamin D2.
Anal DifferentiationEC50 m× 10−11
Calcaemic Action
Ca2+ (Serum) m× 10−6
VDR Binding
IC50 m× 10−10
1,25D3 53 107 23
PRI-1907 6 75 62
PRI-5100 113 86 6
PRI-5101 118 90 5
PRI-5201 3 93 11
PRI-5202 2 81 36
The values obtained for 1α,25-dihydroxyvitamin D3 (1,24D3) are shown for comparison. The EC50
for differentiating potency is the value that drives half-maximal differentiation of the promyeloid
cell line HL60 towards neutrophils. Calcium levels are the mean of the values obtained for five mice
treated with 0.3 µg/kg of 1,25D3 or an analogue every other day for 3 weeks and measured on day
21. The serum calcium level in ethanol-treated mice was 62 µM. The analogues PRI-1907, PRI-5201,
and PRI-5202 are more potent differentiating agents than 1,25D3 and have a lower calcemic action.
Quite unexpectedly, both (24E) and the new (24Z) analogues are equipotent in decreasing the
cloning capacity and the proliferative activity of the human colon cancer cells HT-29 [26]. These cells are
refractory to the anti-proliferative action of the chemotherapeutic agent 5-flurouracil. Both of the C-25
diethyl analogues, PRI-1907 and PRI-1917, decreased the level of expression of stemness-related genes,
while both dimethyl analogues, PRI-1906 and PRI-1916, were not able to downregulate these genes.
Therefore, the new geometric analogues, PRI-1907 and PRI-1917, are good candidates for further studies
to examine the benefit to preventing cancer relapse. In this regard, they act to decrease the proliferative
capacity of cells that initiate tumor regrowth, by virtue of downregulating stemness-related genes.
The analogues might be useful in post-treatment of cancer patients with conventional reductive
chemotherapy, particularly regarding the reduced calcemic action of PRI-1907 and the newer analogues
of 1,25D2 (see Table 1) [26].
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6. CD-Ring Modifications of Vitamin D
There is evidence to support the viewpoint that methyl substituents at C-13 of 13,13-dimethyl-
des-C,D-1,25-dihydroxy-2-methylene-19-nor-vitamin D3 mimic the C-ring of 1,25D3. The 13,13-
dimethyl des-C,D-analogue of (20S)-1α,25-dihydroxy-2-methylene-19-nor vitamin D3 (Figure 2) still
retains much of the activity of vitD [34]. As predicted [29] and confirmed recently [35], even an
extensive modification of the CD-ring does not affect the functional activity of vitD as long as the
three-dimensional (3D) arrangement of the three 1α, 3, and 25 hydroxyls, responsible for VDR binding,
is preserved. As expected, a number of CD-ring modifications resulted in a lowering or complete
loss of the undesired calcemic action regarding the development of a potent agent that selectively
drives differentiation [30]. A lowering of calcemic activity is also the case for a novel class of five
des-C analogues with the CD-ring fragment partially replaced by an alkyl chain to mimic the C-ring
and an aromatic m-phenylene ring replacing the D-ring (Figure 5). Docking studies to the human
ligand-binding domain of the VDR led to the design of these analogues. The analogue with an
ethyl substituent to mimic the missing C-ring is active against breast cancer cells and, as expected,
has negligible calcemic action [36]. These analogues provide important information about the
structure–activity relationships regarding CD-ring modifications. This novel class of aromatic-based
vitamin D analogues also confirmed that retaining the network of hydrogen bonds of 1,25D3 is
crucial for transactivation activity and that aromatic modification of the CD-ring fragment abolishes
calcemic activity.
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7. Future Directions
As described, various modifications to vitD underlie the search for a new drug candidate.
Beneficial modifications are those to the A-ring, the triene system, the CD-ring fragment, and the
side-chain. An old viewpoint was to make very subtle a si l ifi ti s. The current
understanding to obtaining the most potent VDR agonist is to combine several modifications at
various parts of the molecule. However, the number of possible combinations is numerous. The route
to the best combinations remains elusive, because the ultimate outcome of combinations is quite
unpredictable. They might result in enhancement or in a complete loss of activity. Even so, several
vitamin D super-agonists have been rationally designed and synthesized.
Intuition has mostly driven the design of new vitamin D analogues, coupled with trial and error.
A crystal of the full-length native VDR that is suitable for X-ray diffraction study is presently not
available. In this case, a classical model [37] that makes use of a truncated VDR protein remains the
only available approach to examining the interactions of vitDs with the VDR. This artificial VDR
protein has the flexible hinge region cut off to improve the ability of the residual VDR to crystallize.
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The accumulating of more and more data leads to the viewpoint that the standing model might
be of limited significance, because the resulting solid-state structures of various analogues show
overlapping of the functional hydroxyls. Very recently, a study of a panel of five analogues of very
different structures recorded no detectable differences regarding binding to the VDR [36].
A common understanding is that crystallography plays the major role as the only direct method for
studying analogues per se and their protein complexes to reveal structure versus activity relationships.
Relative spectroscopic methods, such as high frequency nuclear magnetic resonance (900 MHz) [38], are
still of a very limited use, as not enough data have been accumulated for a complete signal assignment.
Up to now and for complexes of vitDs and the VDR, there is only low-resolution crystallographic
data, usually well above 2 Å. We might expect that high-resolution crystallographic data, below
0.5 Å, will give a much better insight into the structural differences between the VDR complexed with
various analogues.
However, to make substantial progress and ensure the design of analogues in a truly rational
manner an entirely new crystallographic approach is required. It is highly desirable to obtain single
crystal high-resolution data of the native VDR, other than for a truncated model protein. Considering
the recent developments of crystallography, the time is right to make a concerted effort to obtain
the crystal structure of the full-length human VDR per se and complexed with vitDs. Automated
high-throughput robots now crystallize proteins up to three times larger than the VDR. Additionally,
consideration of modern cryo-electron microscopy as a tool for examining a native VDR-retinoid X
receptor (RXR) complex is worthwhile. Success in the above directions will open a new era that should
reveal the real relationships between the structure and the biological activity of vitDs.
To understand the various biological roles of the VDR there is a need to develop an antagonist of
the VDR. The rational design of a potent antagonist is much more difficult than designing an agonist,
because there are only few antagonistic structures for use to examine correlations between structure
and function. Additionally, computerized docking approaches are especially useful for designing
agonists, and the same method is useful to the design of antagonists. The crystal structure of the
full-length VDR will be valuable to the design of an antagonist.
8. Concluding Remarks
As outlined, the precise nature of modifications to the structure of vitD is important to the gain
and loss of particular biological actions. The modified analogues, in turn, are important to developing
a better understanding of how vitD can mediate a variety of different biological roles. Of particular
interest is the generation of vitDs that are potent differentiating agents and lack calcemic action, for use
in studies of cell differentiation and as potential anti-cancer agents. Work over a number of years
has generated a range of analogues with very different modifications to the structure of vitD and has
correlated their structures with biological actions. A number of important structure–activity rules
have emerged (see Figure 6). Analogues with an aromatic modification of the CD-ring fragment have
a reduced calcemic action. The hydrogen bonds of the natural 1,25D3 are crucial for transactivation
activity, and vitDs with the (24E) side-chain geometry combined A-ring modifications are potent
anti-proliferative and differentiating agents. Too many structural modifications, a combination of
four in the case of PRI-1734, led to a complete loss of biological activity. A rigid and straight (24E)
geometry of the side-chain confers resistance to catabolism via enzymatic hydroxylation by hCYP24A1.
The provision of a better understanding of how vitD and analogues bind to VDR is also essential to
unraveling function. In this regard, the existence of the vitD A-ring in the β-chair conformation, rather
than the α-chair conformation, is essential to the differentiating activity of analogues. The application
of the rules to activity gained so far should allow analogues to be refined further regarding potency
and selectivity.
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